\documentclass[aspectratio=169]{beamer}
%\documentclass[handout]{beamer}

% language settings
%\usepackage{fontspec, polyglossia}
%\setdefaultlanguage{magyar}

% common packages
\usepackage{amsmath, multimedia, hyperref, color, multirow}
%\usepackage{graphicx}

% TikZ
\usepackage{tikz}
%\usetikzlibrary{arrows.meta, decorations.pathmorphing, decorations.pathreplacing, shapes.geometric,mindmap}
%\usetikzlibrary{shapes.geometric,fadings,bayesnet}

% beamer styles
\mode<presentation>{
%\usetheme{Warsaw}
%\usetheme{Antibes}
\usecolortheme{beaver}
%\usecolortheme{seahorse}
%\usefonttheme{structureitalicserif}
\setbeamercovered{transparent}
}
\setbeamertemplate{blocks}[rounded][shadow=true]
\AtBeginSubsection[]{
  \begin{frame}<beamer>{Contents}
    \tableofcontents[currentsection,currentsubsection]
  \end{frame}
}
%\useoutertheme[]{tree}

% title, etc
\title{The Main Title Naming Key Concepts}
\subtitle{A subtitle may be shorter and more technical}
\author{Attila Jones}
\date{}

\begin{document}

\section{Bumetanide paper}

\begin{frame}{Current \& ongoing work}
\begin{itemize}
\item network based drug repurposing
\begin{itemize}
\item computing: NIAIRPCLOUD, NIH HPC (Biowulf)
\item visualize target---AD gene pathways
\item refine drug---target network: activities
\end{itemize}
\item NCI workshop: Rational Drug Discovery
\begin{itemize}
\item ChEMBL
\end{itemize}
\item drug repurposing with CMap\footnote{Connectivity Map}/
  LINCS\footnote{Library of Integrated Network-based Cellular Signatures}
\item Bumetanide paper
\end{itemize}
\end{frame}

\begin{frame}{The signature reversal (``flip'') principle}
\begin{itemize}
%\item differential expression (DE) signature of disease
\item \alert{Drugs that reverse DE signature treat disease	more effectively.}
\item causality
\begin{enumerate}
	\item signature $\rightarrow$ disease
	\item signature $\leftarrow$ disease
\end{enumerate}
\item disease subtypes
\end{itemize}
\end{frame}

\begin{frame}{How it works}
\begin{itemize}
  \item Can perturbation $B$ revert the transcriptomic signature of perturbation $A$?
  \item $\widehat{\mathrm{corr}}(S_{A\alpha}, S_{B\beta}) < 0$ ?
\end{itemize}
\vfill
\begin{tabular}{r|cc|}
  \hline
  perturbation & $A$ & $B$ \\
  tissue/organism & $\alpha$ & $\beta$ \\
  signature & $S_{A\alpha}$ & $S_{B\beta}$ \\
  \hline
\end{tabular}
\end{frame}

\begin{frame}{How it works: example}
\begin{itemize}
  \item Can drug $B$ revert the transcriptomic signature of Alzheimer's?
  %\item $\widehat{\mathrm{corr}}(S_{A\alpha}, S_{B\beta}) < 0$ ?
\end{itemize}
\vfill
\begin{tabular}{r|cc|}
  & disease signature & drug signature \\
  \hline
  perturbation & Alzheimer's & drug $B$ \\
  tissue & cortex & PC3 cell line \\
  organism & human & human\\
  signature & $U, D$: up, down genes & CMap \\
  \hline
\end{tabular}
\end{frame}

\begin{frame}{}
\begin{columns}[t]
\begin{column}{0.45\textwidth}
CMap flavors: tools, methods
\begin{enumerate}
\item ?  (Sudhir)
\item clue.io (Broad)
\item L1000CDS2 (Mount Sinai)
\item Sirota et al (Bumetanide study)
\end{enumerate}
\end{column}

\begin{column}{0.55\textwidth}

  \includegraphics[width=\textwidth]{../../../notebooks/2021-10-04-CMap-discussion/named-figure/cmap-tools-consistency.pdf}
\end{column}
\end{columns}
\end{frame}

\begin{frame}{CMap and network-based screen disagree}
\begin{columns}[t]
\begin{column}{0.4\textwidth}
  input gene sets

  \includegraphics[width=\textwidth]{../../../notebooks/2021-10-04-CMap-discussion/named-figure/sudhir-up-down-ADknowledge.pdf}

  \vfill
  linear regression
  \begin{eqnarray*}
    \hat{\beta} &=& -0.009 \\
    \hat{\sigma} &=& 0.003 \\
    p &=& 0.0007
  \end{eqnarray*}
\end{column}

\begin{column}{0.4\textwidth}

  \includegraphics[width=\textwidth]{../../../notebooks/2021-10-04-CMap-discussion/named-figure/sudhir-lincs-rank.pdf}
\end{column}

\end{columns}
\end{frame}

\begin{frame}
  \begin{itemize}
    \item AD incipient proteomic signature
      \begin{enumerate}
        \item network-based screen
        \item CMap
      \end{enumerate}
  \end{itemize}
\end{frame}

\end{document}

\begin{columns}[t]
\begin{column}{0.5\textwidth}

\end{column}

\begin{column}{0.5\textwidth}

\end{column}
\end{columns}

\begin{frame}{CMap and network-based screen disagree}
\begin{columns}[t]
\begin{column}{0.4\textwidth}

  \includegraphics[width=\textwidth]{../../../notebooks/2021-10-04-CMap-discussion/named-figure/sudhir-up-down-ADknowledge.pdf}
\end{column}

\begin{column}{0.4\textwidth}

  \includegraphics[width=\textwidth]{../../../notebooks/2021-10-04-CMap-discussion/named-figure/sudhir-lincs-rank.pdf}
\end{column}

\begin{column}{0.1\textwidth}

  \begin{tabular}{rl}
    $\hat{\beta}$ & -0.009 \\
    $\hat{\sigma}$ & 0.003 \\
    $p$ & 0.0007 \\
  \end{tabular}
\end{column}
\end{columns}
\end{frame}
